These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 8787054)
1. Serum (circulating) tumor markers for breast cancer. Hayes DF Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054 [TBL] [Abstract][Full Text] [Related]
2. Tumor markers for breast cancer. Hayes DF Ann Oncol; 1993 Dec; 4(10):807-19. PubMed ID: 8117599 [TBL] [Abstract][Full Text] [Related]
3. Tumor markers for breast cancer. Current utilities and future prospects. Hayes DF Hematol Oncol Clin North Am; 1994 Jun; 8(3):485-506. PubMed ID: 8707769 [TBL] [Abstract][Full Text] [Related]
4. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487 [TBL] [Abstract][Full Text] [Related]
5. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247 [TBL] [Abstract][Full Text] [Related]
6. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
7. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872 [TBL] [Abstract][Full Text] [Related]
8. CEA, TPA and CA 15.3 in tissue and serum of breast cancer patients. Saccani Jotti G; Grassi C; Fontanesi M; Becchi G; Gion M Int J Biol Markers; 1992; 7(4):265-6. PubMed ID: 1491185 [No Abstract] [Full Text] [Related]
9. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854 [TBL] [Abstract][Full Text] [Related]
10. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients. Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361 [TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985 [TBL] [Abstract][Full Text] [Related]
12. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J Oncology; 1994; 51(6):491-6. PubMed ID: 7970492 [TBL] [Abstract][Full Text] [Related]
13. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526 [TBL] [Abstract][Full Text] [Related]
14. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts. Nicolini A; Carpi A; Ferrari P; Anselmi L Int J Biol Markers; 1997; 12(4):181-6. PubMed ID: 9582609 [No Abstract] [Full Text] [Related]
15. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3. van Dalen A Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693 [TBL] [Abstract][Full Text] [Related]
16. CA 549 and SP2: new tumor markers in breast cancer. Torres M; Jiménez-Heffernan A; García A; Valverde A; Mateo A Int J Biol Markers; 1990; 5(2):97-8. PubMed ID: 2283484 [No Abstract] [Full Text] [Related]
17. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606 [TBL] [Abstract][Full Text] [Related]
18. Use of serum tumor markers for the diagnosis and follow-up of breast cancer. Barrenetxea G; Schneider J; Llorente MF Oncology; 1998; 55(5):447-9. PubMed ID: 9732223 [No Abstract] [Full Text] [Related]
19. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Devine PL; Duroux MA; Quin RJ; McGuckin MA; Joy GJ; Ward BG; Pollard CW Breast Cancer Res Treat; 1995 Jun; 34(3):245-51. PubMed ID: 7579489 [TBL] [Abstract][Full Text] [Related]
20. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Nicolini A; Carpi A; Ferrari P; Anselmi L; Spinelli C; Conte M; Miccoli P Br J Cancer; 2000 Dec; 83(11):1412-7. PubMed ID: 11076646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]